SER · Serina Therapeutics, Inc.

Substantial doubt about the company's ability to continue as a going concern.

“Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations within one year of the unaudited condensed consolidated interim financial statements issuance date, raise substantial doubt about our ability to continue as a going concern.”